832735-41-8

Usage

Uses

Used in Medicinal Chemistry:
4-(5-Bromopyrimidin-2-yloxy)piperidine-1-carboxylic acid tert-butyl is used as a building block for the synthesis of various pharmaceutical agents. Its structural attributes and functional groups contribute to the creation of diverse bioactive compounds, enhancing the development of novel therapeutics.
Used in Drug Development:
In the pharmaceutical industry, 4-(5-Bromopyrimidin-2-yloxy)piperidine-1-carboxylic acid tert-butyl is utilized as a key intermediate for the production of bioactive molecules. Its bromopyrimidine moiety may confer specific biological activity or target engagement, making it a promising scaffold for the advancement of innovative medications.
Used in Targeted Drug Design:
4-(5-Bromopyrimidin-2-yloxy)piperidine-1-carboxylic acid tert-butyl is employed in the design of targeted drugs, where its unique structural features can be leveraged to improve the selectivity and efficacy of therapeutic agents. This can lead to more effective treatments with fewer side effects.

InChI:InChI=1/C14H20BrN3O3/c1-14(2,3)21-13(19)18-6-4-11(5-7-18)20-12-16-8-10(15)9-17-12/h8-9,11H,4-7H2,1-3H3

Upstream product

• 32779-36-5 5-Bromo-2-chloropyrimidine 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 

Downstream Products

• 1189551-44-7 t-butyl 4-[(5-phenylpyrimidin-2-yl)oxy]piperidine-1-carboxylate 
• 1189551-86-7 t-butyl 4-[(5-pyridin-2-ylpyrimidin-2-yl)oxy]piperidine-1-carboxylate 
• 832735-42-9 2-(1-tert-butoxycarbonylpiperidine-4-yloxy)-5-(4-cyanophenyl)pyrimidine 

Relevant academic research and scientific papers

INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF

The invention provides novel chemical compounds useful for treating cancer, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.

HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE

The present invention provides a novel hydroxyquinoxaline carboxamide derivative that is useful for preventing and/or treating blood coagulation disorders. A compound represented by formula (i), or a pharmacologically acceptable salt thereof: wherein, each of R1 and R2 independently represents a group such as a hydrogen atom or a halogen atom; R3 represents a group such as a hydrogen atom; each of R4 and R5 independently represents a group such as a hydrogen atom, a halogen atom or a C1-4 alkyl group; each of R6 and R7 independently represents a hydrogen atom or a C1-4 alkyl group; X represents a group such as a C3-10 cycloalkyl group, C6-10 aryl group or a 5- to 10-membered heterocyclic group, which may be substituted with substituent(s) selected from substituent group α; Y represents a group such as -CO-, -O- or -NRa-, and Ra represents a group such as a hydrogen atom or a C1-4 alkyl group.

HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE

Provided are compounds of a formula (I) and their pharmaceutically-acceptable salts: wherein X1, X2 and X3 each independently represent N or CH; W represents the following formula (II): or the following formula (III): Y represents a group of a formula (IV): The compounds have a histamine-H3 receptor antagonistic or inverse-agonistic activity and are useful for remedy and/or prevention of obesity, diabetes, hormone secretion disorders, sleep disorders, etc.

TREATMENT OF STROKE WITH HISTAMINE H3 INVERSE AGONISTS OR HISTAMINE H3 ANTAGONISTS

Histamine H3 inverse agonists or histamine H3 antagonists are useful, alone or in combination with an anti-stroke agent, for treating stroke.

TREATMENT OF TREMOR WITH HISTAMINE H3 INVERSE AGONISTS OR HISTAMINE H3 ANTAGONISTS

Histamine H3 inverse agonists or histamine H3 antagonists are useful, alone or in combination with a neuroleptic agent, for treating or preventing movement disorders, including tremor, such as essential tremor, and tremor associated with Parkinson’s disea